Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q3 2022 · 10-Q
Revenue$1.50M$1.50M+110.7% vs Q3 2021 Net Income-$847.00K-$847.00KN/M vs Q3 2021 EPS, diluted—
Gross Profit$752,000+114.9% Operating Income-$943,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Operating Cash Flowderived-$939,000N/M Margins · derivedGross margin50.1%+1.0 pt vs Q3 2021
Operating margin-62.9%+141.5 pt vs Q3 2021
Net margin-56.5%+145.1 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end